Business
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy cells, today issued the following letter to shareholders from Chief Executive Officer, Oren Gilad. The letter highlights the Company’s ongoing clinical progress, operational execution, and plans for 2026. Dear Shareholders -- As 2
About this update from Aprea Therapeutics, Inc.
[{"type":"image","alt":"Aprea Therapeutics","displaySize":"","headline":null,"caption":"Aprea Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bNZPaglg_h8I4EDLnMTyIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0","width":300,"height":73}},"lazy":false},{"type":"text","content":"DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy cells, today issued the following letter to shareholders from Chief Executive Officer, Oren Gilad. The letter highlights the Company’s ongoing clinical progress, operational execution, and plans for 2026.","length":474,"tagName":"p"},{"type":"text","content":"Dear Shareholders --","length":20,"tagName":"p"},{"type":"text","content":"As 2025 comes to a close, I am proud of what Aprea has accomplished over the past 12 months and excited for the year ahead. This year, we achieved meaningful milestones that we believe validate our approach and position us for long-term growth. These accomplishments reflect our team’s hard work and dedication, and we are pleased to share them with you.","length":354,"tagName":"p"},{"type":"text","content":"WEE1 Inhibitor Program, APR-1051","length":32,"tagName":"p"},{"type":"text","content":"Our lead program, APR-1051, a next-generation WEE1 inhibitor, continues to demonstrate promising anti-tumor activity in our ongoing ACESOT-1051 dose-escalation study. We are enrolling patients in the 220 mg cohort (Cohort 8), and so far, through the 150mg dose, the treatment has been well tolerated with no dose-limiting toxicities (DLTs) or unexpected safety findings or issues.","length":380,"tagName":"p"},{"type":"text","content":"We have observed disease stabilization in several patients, with the longest duration of treatment reaching 222 days. The most notable response to date is a 15% reduction in tumor burden. Encouragingly, the number of patients achieving disease stabilization appears to increase with higher doses.1","length...